PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Update on Effective Management Strategies in Patients with Dimethylfumarate Flushing Induced: Real Life Preliminary Results of An Observational Psoriatic Patients Cohort Study
Version 1
: Received: 25 August 2020 / Approved: 26 August 2020 / Online: 26 August 2020 (10:59:37 CEST)
How to cite:
Mazzilli, S.; Dattola, A.; Costanza, T.G.; Orlandi, A.; Aquilano, K.; Lettieri-Barbato, D.; Lozzi, F.; Dika, E.; Lanna, C.; Bianchi, L.; Campione, E. Update on Effective Management Strategies in Patients with Dimethylfumarate Flushing Induced: Real Life Preliminary Results of An Observational Psoriatic Patients Cohort Study. Preprints2020, 2020080582 (doi: 10.20944/preprints202008.0582.v1).
Mazzilli, S.; Dattola, A.; Costanza, T.G.; Orlandi, A.; Aquilano, K.; Lettieri-Barbato, D.; Lozzi, F.; Dika, E.; Lanna, C.; Bianchi, L.; Campione, E. Update on Effective Management Strategies in Patients with Dimethylfumarate Flushing Induced: Real Life Preliminary Results of An Observational Psoriatic Patients Cohort Study. Preprints 2020, 2020080582 (doi: 10.20944/preprints202008.0582.v1).
Cite as:
Mazzilli, S.; Dattola, A.; Costanza, T.G.; Orlandi, A.; Aquilano, K.; Lettieri-Barbato, D.; Lozzi, F.; Dika, E.; Lanna, C.; Bianchi, L.; Campione, E. Update on Effective Management Strategies in Patients with Dimethylfumarate Flushing Induced: Real Life Preliminary Results of An Observational Psoriatic Patients Cohort Study. Preprints2020, 2020080582 (doi: 10.20944/preprints202008.0582.v1).
Mazzilli, S.; Dattola, A.; Costanza, T.G.; Orlandi, A.; Aquilano, K.; Lettieri-Barbato, D.; Lozzi, F.; Dika, E.; Lanna, C.; Bianchi, L.; Campione, E. Update on Effective Management Strategies in Patients with Dimethylfumarate Flushing Induced: Real Life Preliminary Results of An Observational Psoriatic Patients Cohort Study. Preprints 2020, 2020080582 (doi: 10.20944/preprints202008.0582.v1).
Abstract
Background: Dimethylfumarate (DMF) is an orally administered fumaric acid esters (FAE) approved for plaque psoriasis. The most represented adverse event for incidence reported in all studies regarding multiple sclerosis and psoriasis treatment was flushing followed by gastrointestinal and lymphopenia (AEs). We report our experience on effective management strategies in patients with dimethylfumarate fushing induced. Methods: The purpose of our study is addressed to propose feasibles strategies able to mitigate adverse events developing in order to improve therapy compliance. We report our real life experience of 20 patients affected by mild to moderate plaque psoriasis in treatement with DMF 10 male and 10 female, with 45,4 years old mean age underwent to a reducing a daily dosage regimen with DMF from 120 mg to 30 mg tablets. Patients experience flushing around 30-45 minutes after assuming the medication.per day. Results: Patients achieving a good adherence and efficacious results in terms of PASI 75 reduction after 16 weeks of treatment. Conclusion: DMF is efficacious and has a favorable benefit–risk profile, thanks to the possibility of implementing posology strategies in order to optimize adherence to the therapy.
Subject Areas
flushing; dimethylfumarate; psoriasis
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sara Mazzilli
*
,
,
Commenter:
The commenter has declared there is no conflict of interests.
Commenter:
The commenter has declared there is no conflict of interests.